A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

281

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

December 24, 2027

Study Completion Date

May 25, 2029

Conditions
B Cell Precursor Acute Lymphoblastic Leukemia
Interventions
DRUG

Blinatumomab

Blinatumomab will be administered as a subcutaneous (SC) injection.

Trial Locations (44)

1090

COMPLETED

Universitaetsklinikum Allgemeines Krankenhaus Wien, Vienna

2145

RECRUITING

Westmead Hospital, Westmead

3004

RECRUITING

The Alfred Hospital, Melbourne

3084

RECRUITING

Austin Health, Austin Hospital, Heidelberg

3168

RECRUITING

Monash Medical Centre, Clayton

5000

RECRUITING

Royal Adelaide Hospital, Adelaide

10016

RECRUITING

New York University Grossman School of Medicine and New York University Langone Hospitals, New York

12203

RECRUITING

Charite - Universitaetsmedizin Berlin, Campus Benjamin Franklin, Berlin

20132

COMPLETED

IRCCS Ospedale San Raffaele, Milan

24127

RECRUITING

Azienda Socio Sanitaria Territoriale Papa Giovanni xxiii, Bergamo

25123

RECRUITING

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

31008

RECRUITING

Clinica Universidad de Navarra, Pamplona

31059

RECRUITING

Institut Universitaire du Cancer Toulouse Oncopole, Toulouse

34214

RECRUITING

Bagcilar Medipol Mega Universite Hastanesi, Istanbul

35575

RECRUITING

Izmir Ekonomi Universitesi Medical Point Hastanesi, Izmir

37007

RECRUITING

Complejo Asistencial Universitario de Salamanca Hospital Universitario de Salamanca, Salamanca

40138

RECRUITING

IRCCS Azienda Ospedaliero Universitaria di Bologna Policlinico di Sant Orsola, Bologna

41013

COMPLETED

Hospital Universitario Virgen del Rocio, Seville

46010

RECRUITING

Hospital Clinico Universitario de Valencia, Valencia

50937

RECRUITING

Universitaetsklinikum Koeln, Cologne

59000

RECRUITING

Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez, Lille

72076

COMPLETED

Universitaetsklinikum Tuebingen, Tübingen

75012

RECRUITING

Hopital Saint Antoine, Paris

77030

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

86156

RECRUITING

Universitaetsklinikum Augsburg, Augsburg

89081

RECRUITING

Universitatsklinikum Ulm, Ulm

91010

RECRUITING

City of Hope National Medical Center, Duarte

98109-1023

RECRUITING

Fred Hutchinson Cancer Center, Seattle

COMPLETED

Fred Hutchinson Cancer Center, Seattle

T2N 2T9

RECRUITING

Arthur J E Child Comprehensive Cancer Centre, Calgary

T6G 2P4

RECRUITING

University of Alberta, Edmonton

V5Z 1M9

RECRUITING

Vancouver General Hospital, Gordon and Leslie Diamond Health Care Centre, Vancouver

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

06202

RECRUITING

Centre Hospitalier Universitaire de Nice - Hopital l Archet, Nice

07747

RECRUITING

Universitaetsklinikum Jena, Jena

04103

RECRUITING

Universitaetsklinikum Leipzig, Leipzig

00161

RECRUITING

Azienda Ospedaliera Policlinico Umberto I, Roma

010-8543

RECRUITING

Akita University Hospital, Akita

277-8577

RECRUITING

National Cancer Center Hospital East, Kashiwa-shi

960-1295

RECRUITING

Fukushima Medical University Hospital, Fukushima

232-0024

RECRUITING

Yokohama City University Medical Center, Yokohama

3015 CN

RECRUITING

Erasmus Medisch Centrum, Rotterdam

08916

RECRUITING

Institut Catala d Oncologia Badalona Hospital Universitari Germans Trias i Pujol, Badalona

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

BeiGene

INDUSTRY

lead

Amgen

INDUSTRY

NCT04521231 - A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL | Biotech Hunter | Biotech Hunter